Insights

Strategic partnerships Asylia has already secured a collaboration with MD Anderson Cancer Center and received a seed grant from CPRIT, signaling openness to co-development and academia-driven research. This suggests sales opportunities around joint research programs, licensing discussions, and sponsored development initiatives with leading cancer centers.

Licensing leverage The exclusive worldwide license agreement with MD Anderson indicates potential for additional license or co-development deals with prestigious institutions or biotechs aiming to access novel antigen presentation modulation therapies for oncology and autoimmune applications.

Early-stage focus Operating as a private, development-stage biotech with a modest revenue base, Asylia may seek input and partnerships to de-risk late-stage progression, including preclinical to clinical collaboration, contract research, and milestone-driven deals aligned with its bootstrapped fundraising.

Targeted therapeutic angle The platform’s emphasis on antigen presentation modulation across cancer models presents sales avenues with translational research partners, contract manufacturing, and immune-oncology program expansions with immune modulation capabilities suitable for pharma and biotech buyers.

Market readiness With a small team and platform-level assets, there is an opportunity to engage CROs, strategic investors, and larger biotech players seeking to augment their oncology pipelines through collaboration, licensing, or acquisition discussions that complement their existing immunotherapy portfolios.

Similar companies to Asylia Therapeutics, Inc.

Asylia Therapeutics, Inc. Tech Stack

Asylia Therapeutics, Inc. uses 8 technology products and services including Amazon Web Services, RSS, WordPress, and more. Explore Asylia Therapeutics, Inc.'s tech stack below.

Asylia Therapeutics, Inc.'s Email Address Formats

Asylia Therapeutics, Inc. uses at least 2 email formats:
Asylia Therapeutics, Inc. Email FormatsExamplePercentage
First.Last@asyliatx.comJohn.Doe@asyliatx.com
67%
First.L@asyliatx.comJohn.D@asyliatx.com
33%

Frequently Asked Questions

What is Asylia Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Asylia Therapeutics, Inc.'s official website is asyliatx.com and has social profiles on LinkedIn.

How much revenue does Asylia Therapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, Asylia Therapeutics, Inc.'s annual revenue is estimated to be <$1M.

What is Asylia Therapeutics, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Asylia Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Asylia Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, Asylia Therapeutics, Inc. has approximately 3 employees across 1 continents, including North America. Key team members include Senior Scientist Preclinical Development: P. M. Explore Asylia Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Asylia Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Asylia Therapeutics, Inc. operates in the Biotechnology industry.

What technology does Asylia Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Asylia Therapeutics, Inc.'s tech stack includes Amazon Web Services, RSS, WordPress, Cloudflare DNS, Amazon ALB, Trustpilot, WP Engine and Nginx.

What is Asylia Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Asylia Therapeutics, Inc.'s email format typically follows the pattern of First.Last@asyliatx.com. Find more Asylia Therapeutics, Inc. email formats with LeadIQ.

When was Asylia Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Asylia Therapeutics, Inc. was founded in 2019.
Asylia Therapeutics, Inc. logo

Asylia Therapeutics, Inc.

BiotechnologyTexas, United States2-10 Employees

Asylia Therapeutics, Inc. is a private, development-stage biotechnology company based in Houston, Texas, founded in August 2019. It concentrates on developing immune-modulating therapies for cancer and autoimmune diseases, addressing conditions that affect millions of Americans each year. Its approach centers on a drug pipeline designed to influence how antigens are presented to the immune system, with preclinical work showing anti-tumor activity across established cancer models.

The company has pursued collaborations with research institutions, including an exclusive worldwide license agreement with The University of Texas MD Anderson Cancer Center announced in 2020. It operates as a small, research-focused organization developing new therapies in the biotechnology field.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
2-10

Section iconFunding & Financials

  • <$1M

    Asylia Therapeutics, Inc.'s revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.